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Abstract
Background:  Stromal cell-derived factor 1 (SDF-1 or CXCL12) is chemotaxic for CXCR4
expressing bone marrow-derived cells. It functions in brain embryonic development and in
response to ischemic injury in helping guide neuroblast migration and vasculogenesis. In
experimental adult stroke models SDF-1 is expressed perivascularly in the injured region up to 30
days after the injury, suggesting it could be a therapeutic target for tissue repair strategies. We
hypothesized that SDF-1 would be expressed in similar temporal and spatial patterns following
hypoxic-ischemic (HI) injury in neonatal brain.
Results: Twenty-five 7-day-old C57BL/J mice underwent HI injury. SDF-1 expression was up
regulated up to 7 days after the injury but not at the later time points. The chief sites of SDF-1 up
regulation were astrocytes, their foot processes along blood vessels and endothelial cells.
Conclusion: The localization of SDF-1 along blood vessels in the HI injury zone suggests that these
perivascular areas are where chemotaxic signaling for cellular recruitment originates and that
reactive astrocytes are major mediators of this process. The associated endothelium is likely to be
the site for vascular attachment and diapedesis of CXCR4 receptor expressing cells to enter the
injured tissue. Here we show that, relative to adults, neonates have a significantly smaller window
of opportunity for SDF-1 based vascular chemotaxic recruitment of bone marrow-derived cells.
Therefore, without modification, following neonatal HI injury there is only a narrow period of time
for endogenous SDF-1 mediated chemotaxis and recruitment of reparative cells, including
exogenously administered stem/progenitor cells.
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Background
Hypoxic-ischemic (HI) injury to the brain is a significant
cause of neurological morbidity in infants. The resultant
severe and longstanding disability to infants has provided
impetus for exploring aggressive therapies that give prom-
ise of injury reversal. Transplantation of stem cells has
emerged as a possible modality to help improve function
in damaged tissues [1].
In organ-specific injury models, bone marrow cells have
been shown to accumulate at the site of injury and to dif-
ferentiate into tissue specific cells [2-5]. Chen and col-
leagues [6] reported that intravenously administered
marrow stromal cells accumulate in the site of ischemic
brain injury, with a small percentage expressing neuronal
markers. Additionally, Hess et al. [7,8] have demonstrated
that, following temporary ischemia, endogenous murine
bone marrow cells give rise to perivascular/mural cells,
microglial cells, and a limited number of cells positive for
the neuronal marker, NeuN. However, it is unclear if the
NeuN positive cells develop into mature neurons.
Among the milieu of chemicals expressed in the injured
microenvironment, the chemotactic chemokine, stromal
cell derived factor-1 (SDF-1 or CXCL12), has emerged as a
major attractant of reparative cells. SDF-1 and its receptor,
CXCR4, play a critical role in both engraftment of hemat-
opoietic stem cells into bone marrow and the mobiliza-
tion of stem/progenitor cells from bone marrow niches
into the peripheral circulation where these cells are then
available for delivery to sites of peripheral injury [9-11].
In addition to functioning in the hematopoietic system,
CXCR4 positive cells respond to SDF-1 signals in non-
hematopoietic injured organs [12]. That exogenous bone
marrow-derived cells home to and migrate within the site
of injury suggests that the brain's response to injury pro-
duces signals that attract these cells [7,8,13]. Functionally,
SDF-1 is a powerful chemoattractant for CXCR4-express-
ing bone marrow derived cells, including putative bone
marrow stem/progenitor cells such as CD34+ cells both in
vitro and in vivo [14].
In addition to targeting hematopoietic cells, the SDF-1/
CXCR4 system is also known to play a critical role in
embryonic brain development and adult injury repair
including neurogenesis, neuroblast migration, and neuro-
SDF-1 Antibody Specificity Figure 2
SDF-1 Antibody Specificity. The polyclonal SDF-1 antibody was tested for non-SDF-1 antigenic interactions and non-spe-
cific tissue binding. Panel A demonstrates the SDF-1 antibody's recognition of SDF-1 antigen on mouse hippocampus. Panel B 
demonstrates that preabsorption of the SDF-1 antibody with recombinant murine SDF-1α completely blocks specific binding of 
the antibody to the tissue with only very low (diffuse background) non-specific binding. Panel C shows that leaving the primary 
(SDF-1) antibody incubation step out of the staining protocol does not result in non-specific binding of the secondary antibody 
or the detection reagents. Scale bar equals 200 µm.
SDF-1 Western blot Figure 1
SDF-1 Western blot. Recombinant murine SDF-1α (25 or 
100 ng per lane) was run on a one-D gel, transferred to 
PVDF membrane and probed with the SDF-1 antibody used 
in the immunohistochemical assays. The western blot dem-
onstrates that the SDF-1 antibody recognizes murine SDF-
1α.BMC Neuroscience 2005, 6:63 http://www.biomedcentral.com/1471-2202/6/63
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nal organization as well as endothelial progenitor cell
recruitment, endothelial cell migration and vasculogene-
sis [15-25].
Therefore, it is important to determine the spatial and
temporal expression of SDF-1 relative to injury; SDF-1
expression patterns may establish not only the location
and duration of the window of opportunity for endog-
enous injury-mediated chemotaxis of reparative cells, but
also the timeframe for therapeutic transplantation and
recruitment of various stem cell populations. Recently, we
showed in an adult mouse model of stroke that SDF-1 is
expressed perivascularly in the injured region up to 30
days after middle cerebral artery occlusion [13], suggest-
Constitutive SDF-1 protein expression at P8 Figure 3
Constitutive SDF-1 protein expression at P8. The left column shows SDF-1 antibody staining of P8 mouse brain (Cy3 – 
red). The middle column shows the corresponding nuclear labelling (bis-benzimide – blue) of the same sections. The right hand 
column shows the merged images. Panels A-C show the distribution of constitutive SDF-1 expression at low power. The 
arrows denote diffuse labelling over the neocortex. Panels C-E demonstrate the hippocampal SDF-1 expression pattern. Panels 
G-I show a high magnification of the hippocampal fissure down through the upper blade of the dentate gyrus granular cell layer. 
The arrowheads point out SDF-1 positive blood vessels. Abbreviations: ca – cornus ammons (CA1, 2, 3), cp – choroid plexus, 
dhc – dorsal hippocampal commissure, ec – external capsule, fi – fimbria hippocampus, fmj – forceps major corpus callosum, 
GrDG – granular layer dentate gyrus, hif – hippocampal fissure, LMol – lacunosum moleculare layer hippocampus, Mol – 
molecular layer dentate gyrus, Or – oriens layer, PoDG – polymorph layer dentate gyrus, Rad – stratum radiatum. All Scale 
bars equal 200 µm.BMC Neuroscience 2005, 6:63 http://www.biomedcentral.com/1471-2202/6/63
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ing that there may be a long post-injury window for hom-
ing of reparative cells. Anticipating that SDF-1 might be a
critical factor in attracting transplanted cells to the injured
area of the neonatal brain, we hypothesized that SDF-1
would be expressed in neonatal hypoxic-ischemic injury
in a temporal and spatial pattern similar to that seen in
adult models of ischemic brain injury.
Results
Spatial expression pattern of SDF-1 in uninjured brain
The SDF-1 antibody used for immunohistochemical
localization of SDF-1 recognizes full length recombinant
murine SDF-1 (Figure 1) and preabsorption with SDF-1
blocks its recognition of antigen on tissue sections (Figure
2). In uninjured (control) neonatal mice (P8 through
P17) endogenous protein expression of SDF-1 in brain is
limited and changes over time (Figures 3, 4, 5). At P8 (Fig-
ure 3) the most prominent SDF-1 expression is within the
hippocampus associated with the hippocampal fissure
and the neighbouring molecular layer of the dentate
gyrus, the hippocampal lacunosum molecular layer, the
dentate gyrus polymorph layer, the stratum radiatum and
the oriens layer. Strong expression is also associated with
cells in the choroid plexus, the neurogenic subventricular
zone, and large cortical neurons in the cingulate and neo-
cortex. Additionally, large white matter tracks such as the
corpus callosum and external capsule, as well as cells of
the meninges, also demonstrate SDF-1 expression. Within
the white matter tracks and the hippocampal fissure
numerous blood vessels are associated with SDF-1 label-
ling (Figure 3). However, unexpectedly, the granular cell
layer of the dentate gyrus, CA and layer V neurocortical
neurons do not show strong immunohistochemical stain-
ing for SDF-1 (Figure 3). There is some shift in SDF-1 pro-
tein expression with time. By P14 the hippocampal
expression changes slightly (Figure 4). Expression associ-
ated with the hippocampal fissure is reduced while there
is increased expression in hippocampal areas associated
with dendritic arborization and axonal fields, including
the dentate gyrus polymorph layer, the molecular layer of
the dentate gyrus, the hippocampal lacunosum molecular
layer and the stratum radiatum (Figure 4).
Changes in spatial expression following HI injury
Following HI injury the endogenous constitutive expres-
sion in the large neurons of the cingulate and neocortex is
lost. However, at the same time SDF-1 expression is dra-
matically up regulated in not only areas directly affected
by HI, but also in the choroid plexus and by mesothelial
cells of the pial meninges (Figures 5 and 6). The expres-
sion of SDF-1 in areas of HI injury principally includes the
hippocampus and striatum (figures 6 and 7). Addition-
ally, there is increased and extensive expression by cells
within the HI side hemisphere white matter, particularly
in the corpus callosum, external capsule and hippocampal
fimbria (Figure 6). Interestingly, the choroid plexus and
meninges expression of SDF-1 increases bilaterally with
HI injury, although the degree of expression in the con-
tralateral choroid plexus appears to be less robust than the
HI side choroid plexus (Figures 5 and 6). This suggests a
generalized injury response that extends beyond the area
of ischemia but potentially within the area affected by
hypoxia.
Temporal expression pattern of SDF-1 following HI injury
The first day after HI injury (P8) patchy SDF-1 expression
was demonstrated around blood vessels and within the
parenchyma in the hippocampus and striatum within the
ischemic hemisphere. By 3 days after HI injury (P10) there
was robust, uniform hippocampal expression of SDF-1 in
Constitutive SDF-1 protein expression at P14 Figure 4
Constitutive SDF-1 protein expression at P14. Panel A shows the pattern of SDF-1 expression (Cy3 – red) at P14 (Scale 
bar equals 200 um). Panel B demonstrates the hippocampal expression of SDF-1 (Cy3 – red) (Scale bar equals 200 µm). Panel 
C shows bis-benzimide nuclear labelling (blue) from the same field as Panel B. Abbreviations: ca – cornus ammons (CA1, 2, 3), 
cp – choroid plexus, GrDG – granular layer dentate gyrus, hif – hippocampal fissure, LMol – lacunosum moleculare layer hip-
pocampus, Mol – molecular layer dentate gyrus, Or – oriens layer, PoDG – polymorph layer dentate gyrus, Py – pyramidal cell 
layer, Rad – stratum radiatum. S – subiculum, scc – splenium corpus callosum.BMC Neuroscience 2005, 6:63 http://www.biomedcentral.com/1471-2202/6/63
Page 5 of 11
(page number not for citation purposes)
the CA1, CA2, CA3 and dentate regions as well as within
the striatum and to a limited degree in the cingulate cortex
(Figures 5, 6, 7). By day 5 after the injury (P12) SDF-1 con-
tinued to be expressed but was significantly reduced in the
hippocampus and striatum. However, its expression was
still increased in the choroid plexus (bilaterally) and was
associated with blood vessels in the white matter of the
corpus callosum and external capsule as well as pial mes-
othelial cells (bilaterally). By day 7 (P14), SDF-1 expres-
sion continued to wane, and by day 10 post-HI injury
(P17) and beyond, expression was reduced below observ-
able levels in the hippocampus, striatum and cortical
areas. The only expression of SDF-1 at these late times was
found along white matter tracts of the corpus callosum
and the alveus and in some sites where normal constitu-
tive expression is observed, specifically the subventricular
zone, choroid plexus and a subset of large cingulate cortex
and neocortical neurons. However, expression appeared
Constitutive and Injury Induced Expression of SDF-1 Figure 5
Constitutive and Injury Induced Expression of SDF-1. All panels are from P10 murine neonates. Panels A-C are from a 
non-Hypoxia-Ischemia (HI) control animal; D-I are from an animal that underwent HI injury three days previously at P7. Panels 
D-F are from the HI injured hemisphere and G-I from the corresponding contralateral (non-ischemic) hemisphere. Panels A, D, 
and G are of the lateral ventricle including the CP, SVZ (arrow) and adjacent striatum (*); arrowheads indicate SDF-1 expres-
sion (Cy3 – red) in the CP, scale bar equals 100 µm. Panels B, E, & H are of the cingulate cortex, arrowheads indicate SDF-1 
expression in neurons, scale bar equals 50 µm. Panels C, F, and I show cortex and meninges, arrowheads indicate SDF-1 
expression in mesothelial cells of the pia, scale bar equals 100 microns. Cell nuclei were identified by bis-benzimide counter-
staining (blue). Abbreviations: choroid plexus (CP) and subventricular zone (SVZ).BMC Neuroscience 2005, 6:63 http://www.biomedcentral.com/1471-2202/6/63
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to be depressed in hippocampal areas that normally
expressed SDF-1.
Cellular expression of SDF-1
For all time points demonstrating injury responsive SDF-
1 expression, cellular expression was in large part local-
ized to GFAP+ reactive astrocytes (Figures 8 and 9). Astro-
cyte associated expression of SDF-1 is frequently found
around small blood vessels, suggesting that this perivascu-
lar expression is related to astrocytic foot processes (Fig-
ures 8 and 9). The lectin RCA-1 labels cell surface
carbohydrate moieties associated with both microglial
and endothelial cells. The punctate RCA+/SDF-1+ label-
ling resembles cellular processes, however, the cell type
demonstrating this co-labeling is uncertain, morphologi-
cally it does not resemble GFAP+/SDF-1+ astrocytic cell
processes or endothelial cell profiles (Figure 10). Some of
the SDF-1+/RCA-1+ profiles do appear to be ramified
microglial cells. However, while a subset of microglia in
the HI injury area co-label with SDF-1 the majority do not
(data not shown). Further, SDF-1 did not co-label with
markers for other process bearing cell types including oli-
godendrocytes (data not shown). Also, as described ear-
lier, choroid plexus and pial epithelial cells demonstrate
SDF-1 expression (Figures 3, 5 and 6).
Discussion
The regulation of SDF-1 may be critical to the incorpora-
tion of a variety of new cells into brain. In contrast to the
prolonged up regulation of SDF-1 following stroke in
adult mice [13], its up regulation in neonatal mice after HI
injury was brief. This may reflect a difference between a
mature, relatively stable, adult brain structure and a more
plastic, still developing, neonatal CNS where there may be
a more active regulation of SDF-1 expression. The timing
of post-HI injury SDF-1 expression suggests that SDF-1
mediated cell homing may be most effective from 3 to 5
days after HI injury in neonatal animals, peaking around
3 days. During this time SDF-1 expression is high around
vascular elements, which may provide a portal of access
for circulating reparative cells to the areas of ischemic
injury.
Another possible explanation for the temporal differences
of SDF-1 expression between injured adult and neonatal
brains may be related to the type of injury. HI injury pro-
duces a more diffuse and graded tissue injury, while mid-
dle cerebral artery occlusion is more focal and discrete.
Constitutive SDF-1 expression
Interestingly, the pattern of peak expression for SDF-1 we
show at postnatal day 10, 3 days after HI injury (Figure 6),
is virtually identical to that recently published by Fel-
szeghy et al for I125 SDF-1α binding to CXCR4 in a rat HI
model, 2 days after HI injury, at postnatal day 9 [26]. In
Felszeghy et al's study the localization of CXCR4 receptors
suggests the distribution of SDF-1 expression. Protein
expression observed in our study, with SDF-1 antibody
probes, is consistent with mRNA expression patterns
assayed by in situ hybridization in previous reports with
some exceptions [26-28]. The SDF-1 mRNA expression
patterns Tham et al and Stumm et al [22,23] show at days
P7 and P9 in rats match protein expression patterns we
detected here at P8 and P10 in mice (Figures 3, 5 and 6).
This includes SDF-1 expression in the meninges, the hip-
pocampal fissure, choroid plexus and the proliferative
subventricular zone. SDF-1 mRNA expression in both in
situ hybridization studies [22,23] was also associated, to a
limited degree, with blood vessels, we saw the same con-
stitutive pattern for SDF-1 immunostaining particularly
with vessels associated with the hippocampal fissure and
with white matter tracks (Figure 3). In the in situ hybridi-
zation studies [22,23] there is a decline in hippocampal
fissure SDF-1 mRNA expression between the early time
points (P7 & P9) and later time points (P14 and P12 –
P21). A similar decrease in hippocampal fissure SDF-1
immunostaining was observed in our study between P8
and P14 (Figures 3 and 4). Of interest, in the in situ
hybridization studies [22,23], there are consistent
increases in SDF-1 mRNA in the dentate gyrus granular
layers, in CA3 (and CA4) and in layer V neocortical neu-
SDF-1 Expression 3 days Post Hypoxia-Ischemia Figure 6
SDF-1 Expression 3 days Post Hypoxia-Ischemia. A 
coronal section from a P10 mouse that underwent hypoxia-
ischemia (with right side ischemia) three days earlier, on 
postnatal day 7, was probed with a Cy3 (red) antibody to 
demonstrate SDF-1 expression. Single arrowheads indicate 
choroid plexus, double arrowheads the hippocampus, the 
large arrow indicates the fimbria of the hippocampus, small 
arrows the corpus callosum and external capsule, the aster-
isk (*) denotes the striatum. All five animals at this time point 
showed equivalent levels of SDF-1.BMC Neuroscience 2005, 6:63 http://www.biomedcentral.com/1471-2202/6/63
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rons between the early time points (P7 & 9) and later time
points (P14 and P12 – P21). However, we did not detect
significant SDF-1 immunolabelling over the cell bodies of
the granular cells at equivalent time points in the mice (P8
– 14). In contrast we did detect immunolabelling in the
molecular and polymorph layers, regions of granular cell
dendritic arborizations and axon fields [27]. This labelling
increased between P8 and P14 (Figures 3 and 4). Similarly
we did not detect strong SDF-1 immunoreactivity over CA
3, 2 or 1 neuronal somas, but we found immunoreactivity
that increased between P8 and P14 in the hippocampal
lacunosum molecular layer, the stratum radiatum and the
oriens layer (Figures 3 and 4), regions that contain the
dendritic and axonal fields for the CA region [27]. Addi-
tionally, the layer V neocortical neurons are reported to
show strong mRNA labelling [22,23], but we only
detected weak diffuse antibody labelling in the area corre-
sponding to layers V and VI in the neocortex (Figure 3).
The discrepancy between the reported neuronal somal
labelling for mRNA [22-24] and the neuropil immunola-
belling for SDF-1 protein we observed may be due to a
lack of sensitivity of the antibody, although we can clearly
detect SDF-1 expressing structures that are reported to
express lower levels of SDF-1 mRNA than dentate gyrus
granular cells, CA and layer V neocortical neurons [22,23].
There may also be differences in SDF-1 transcription and
translation rates as well as message and protein turnover
in different cell populations. Alternatively, this may reflect
that SDF-1 mRNA is synthesized in, and restricted to, the
neuronal somas while in some neurons the protein prod-
uct is mainly exported to cellular processes with little
remaining in the somas. For example, while the reported
dentate gyrus granular cell mRNA expression [22-24] is
more intense than any other location, including the hip-
pocampal fissure, we show that this is at best poorly
labelled immunohistochemically (Figures 3 and 4). In
contrast we demonstrate that regions that reflect the syn-
aptic fields (dendritic and axonal) of the granular cells
(molecular and polymorph layers) have strong immuno-
reactive expression for SDF-1 (Figures 3 and 4) while these
same regions show little mRNA expression for SDF-1 [22-
24]. Further, structures lacking projecting processes,
which could distance mRNA form protein localization,
like the hippocampal fissure, choroid plexus, and menin-
ges, are reported to be strongly labelled for SDF-1 mRNA
by in situ hybridization [22-24] and we demonstrate also
by immunohistochemistry for the SDF-1 protein. There is
precedent for this type of pattern in neonatal hippocam-
pus. Czarnecki et al have recently shown that synaptopo-
din mRNA was restricted to dentate granular layer, and
CA3, cell somas while immunostaining for synaptopodin
protein labeled dendritic layers but not the somas [28].
Temporal Expression of SDF-1 in Hippocampus Post-HI Figure 7
Temporal Expression of SDF-1 in Hippocampus Post-
HI. Shows examples of hippocampal expression of SDF-1 at 
different time points post hypoxia-ischemia (HI) demon-
strated by immunohistochemistry (Cy3 label – red), this 
includes 1 (P8), 3 (P10), 5 (P12), 7 (P14) and 10 (P17) days 
following HI. Panels A-E are from the ischemic hemisphere 
and a-e are from the contralateral hemisphere. M and L 
denote the medial and lateral aspects of the hippocampi 
respectively. Hippocampal regions are indicated: cornu 
ammonis (CA 1, 2 & 3), corpus callosum (CC), and dentate 
gyrus (DG). Cell nuclei were identified by bis-benzimide 
counterstaining (blue). Scale bar equals 200 µm.BMC Neuroscience 2005, 6:63 http://www.biomedcentral.com/1471-2202/6/63
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Injury induced SDF-1 expression
Recently Ceradini et al. demonstrated that SDF-1 gene
expression is regulated by the hypoxia responsive tran-
scription factor HIF-1 [21]. The level of SDF-1 expression
is directly related to the degree of hypoxia such that
hypoxic gradients within tissues correlate with gradients
of SDF-1 gene expression [21]. We have previously shown
in an adult middle cerebral artery occlusion model of
stroke that SDF-1 expression follows a gradient pattern
consistent with the hypoxia gradient in the penumbra
[13]. In our neonatal HI model the hippocampus did not
appear to show a gradient of SDF-1 labeling during peak
expression, rather the labeling was uniform and delimited
by anatomical boundaries. In contrast the striatal expres-
sion did appear to show a gradient of labeling intensity
(Figure 6). Specific cell types may be more sensitive to
hypoxic changes in inducing SDF-1 expression as illus-
trated by changes in constitutive expression of SDF-1 as
well as induced expression in cells that did not show sig-
nificant constitutive expression. For example, subsets of
neocortical neurons responded by decreasing SDF-1
expression in both the hypoxic and HI affected hemi-
spheres while choroid plexus and pial labeling increased
on both sides and astrocytes dramatically expressed SDF-
1 only in the HI hemisphere. This suggests that HIF-1
expression may be differentially induced or that other
transcription factors may be involved as well.
Potential role of SDF-1 in injury repair
SDF-1 and its receptor CXCR4 are emerging as a common
axis for directing the migration of stem cells associated
with injury repair in many systems. Ji et al recently dem-
onstrated that SDF-1 mediates the migration of mesen-
chymal stem cells to the site of injury [29]. Neural
progenitor cells and neuroblasts express CXCR4 and are
attracted by SDF-1α developmentally and following brain
ischemia [25,30-32]. Recently SDF-1 has been shown to
promote neovascularization in somatic tissues and to
recruit bone marrow-derived (BMD) cells to areas of
ischemic injury. In mouse models of peripheral tissue
ischemia, SDF-1 treated animals had increased capillary
density and blood flow compared to controls and
recruited injected endothelial precursor cells (EPC) to
integrate into blood vessels demonstrating vasculogenesis
[16,20,21]. Importantly this SDF-1 induced neovasculari-
zation has been demonstrated to improve perfusion and
function in peripheral tissue ischemic injury models
[16,21,33]. Work from our laboratory shows SDF-1 is up
regulated in the penumbral, or peri-infarct, zone within
hours of acute ischemia in adult mice. This elevated
expression persists in the peri-infarct zone for at least 30
days post-ischemia. Accompanying this we observe bone
marrow-derived cell infiltration, pericyte and microglial
engraftment and neovascularization [13]. Given the
apparent function of SDF-1 to serve as an attractant for
bone marrow-derived cells, including cells associated with
vascular repair and vasculogenesis, as well as for other
stem/progenitor cells, including neural stem cells, this
brief time span of SDF-1 expression, peaking at 3 days
with only limited expression through 7 days after the
injury in neonatal animals, may be critical for the acquisi-
tion of new brain or reparative cells.
The cell type expressing SDF-1 and its localization is
highly related to its function. Previously, we found that
the principal localization of SDF-1 expression following
injury was astrocytic, often strongly associated with small
blood vessels [13]. This was the first demonstration that
activated, or reactive astrocytes, express SDF-1 in vivo fol-
lowing ischemia injury [13]. The current study confirms
and extends our original finding and demonstrates that
SDF-1 expression is massively up regulated in reactive
astrocytes in neonatal HI injury, but for a shorter period
of time relative to adult middle cerebral artery occlusion
ischemia. Recently Imitola [25] also reported SDF-1
expression in reactive astrocytes in an adult HI model. Ear-
lier in vitro studies showed that cultured astrocytes up reg-
ulate SDF-1 expression following exposure to various
cytotoxic or inflammation-inducing agents [34,35]. Addi-
tionally, we have recently shown that there is only mini-
mal proliferation and maturation of astrocytes following
HI, suggesting that the astrocytic expression of SDF-1 fol-
lowing HI originates from existing astrocytes [36].
The influence of SDF-1 upon ischemic recovery in
neonates appears to be restricted to a few days under cir-
cumstances of "normal" endogenous repair. Such a brief
up regulation of SDF-1 in neonatal animals may disad-
vantage their recovery relative to adults. However, it may
SDF-1 and GFAP Co-localization Figure 8
SDF-1 and GFAP Co-localization. Panels A-C are from a 
P10 hippocampus, three days post-HI, from the ischemic 
hemisphere, a-c are from the corresponding contralateral 
hippocampus. Panels A & a demonstrate the astrocyte 
marker GFAP (FITC – green). Panels B & b show SDF-1 
expression (Cy3 – red). Panels C & c indicate the overlap 
between GFAP and SDF-1 labeling. Scale bar equals 100 µm.BMC Neuroscience 2005, 6:63 http://www.biomedcentral.com/1471-2202/6/63
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still may provide a defined time frame in which therapeu-
tically transplanted cells, or autologous stem cells mobi-
lized from the bone marrow, may be able to home,
engraft and differentiate into needed cell types. This may
also provide an opportunity to target engineered cells that
express specific factors to the site of injury. Using the SDF-
1/CXCR4 axis as a vectoral targeting system may also per-
mit local application of cell expressed therapeutic factors
in higher doses than systemic delivery would safely allow.
In adults it may be possible to use the natural up regula-
tion of the SDF-1 for up to 30 days after the injury, while
in neonates such a procedure would have to be carried out
much sooner. If transplantation protocols are carried out
in humans, it may be necessary to find ways of either up
regulating the SDF-1 or engineering the expression of the
chemokine to desired temporal and spatial locals.
Conclusion
SDF-1 up regulation following neonatal HI injury persists
only a few days in comparison to the much longer up reg-
ulation in adult models of stroke. The up regulation in
neonatal HI injury is quite prominent in astrocytes abut-
ting small blood vessels. This process may be critical in
attracting CXCR4 expressing cells to the brain. Awareness
of these events could be helpful in planning stem cell
transplantation therapy delivered via the vascular route.
Methods
Animals
This study was performed in accordance with the guide-
lines provided by the Laboratory Animal Studies Commit-
tee of the Veterans Administration Medical Center
(Augusta, GA) and the Medical College of Georgia. The
mice were housed in individual cages under standard con-
ditions. Offspring were reared with their dams until the
time of surgery, and then until weaning at three weeks of
life.
Surgical procedure and treatment
Twenty-five C57 BL/6 mouse pups underwent permanent
ligation of the left common carotid artery at post-natal
day seven (P7) [37]. A midline cervical incision was made
to expose the left common carotid artery, and a single
suture ligated the artery. The incision was closed with
interrupted 6-0 silk sutures. During the procedure, the
mice were anesthetized with 2% isoflurane. The pups
were then placed with the dams for two hours prior to
placement in an 8% oxygen chamber partially immersed
in a water bath at 37° for 75 minutes.
Animal sacrifice and tissue processing
The pups were sacrificed at P8, P10, P12, P14, P17, P21,
or P35 (respectively, 1, 3, 5, 7, 10, 14 or 28 days after the
injury). At least three animals were sacrificed at each time
point. At the time of sacrifice, the animals were anesthe-
Astrocyte Expression of SDF-1 Figure 9
Astrocyte Expression of SDF-1. GFAP and SDF-1 dual 
labeling is demonstrated by confocal microscopy in P10 mice, 
three days post-HI. Panels A-C, from the striatum, show 
perivascular (arrowheads) astrocyte (GFAP – green) expres-
sion of SDF-1 (red). Panels D-F, from the hippocampus, show 
(arrowhead) similar co-labeling of GFAP (green) astrocyte 
cell bodies and processes for SDF-1 (red). Panels C and F 
show GFAP and SDF-1 co-labeling in merged orthogonal 
views of confocal z stacks. GFAP staining is shown in green 
and SDF-1 staining in Red. Panels A, B, D, and E are single z 
plane field images captured with a 63× objective. Scale bar 
equals 50 µm.
SDF-1 and RCA-1 Co-localization Figure 10
SDF-1 and RCA-1 Co-localization. Figure shows RCA 
and SDF-1 dual labeling in hippocampus from P10 mice three 
days post-HI; RCA-1 labeling in hippocampus (A & D), SDF-1 
expression in hippocampus (B & E), merged RCA-1 and SDF-
1 labeling (C & F). Panels A-C represent 20× objective fields. 
Panels D-E are single z plane fields and panel F is a merged 
orthogonal view of a confocal z stack. The arrowhead points 
out an example of an SDF-1 negative RCA-1 positive cell. 
Scale bar equals 50 µm.BMC Neuroscience 2005, 6:63 http://www.biomedcentral.com/1471-2202/6/63
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tized with 70 mg/kg of ketamine and 15 mg/kg xylazine.
Tissue was fixed by transcardiac perfusion with 0.9%
saline, followed by 4% paraformaldehyde in PBS. Brains
were removed and post-fixed in 4% paraformaldehyde for
4 hours, cut into 3–5 mm sections, and continued in 4%
paraformaldehyde for an additional 20 hours. Tissue was
then dehydrated in an ethanol series, cleared in xylene,
and infiltrated and embedded in PolyFin Embedding and
Infiltration Wax (TBS Biomedical Sciences, Durham, NC).
Paraffin embedded tissue was sectioned 5 µ thick and
mounted on Superfrost Plus slides (Fisher Scientific).
Immunohistochemistry
Section processing, antigen retrieval and immunostaining
methods have been previously described [13,36] Briefly,
slide mounted sections were deparaffinized through 3
xylene changes followed by rehydration in an alcohol
dilution series. Sections were permeablized in 0.1% Tri-
ton-X 100 in PBS for ten minutes, followed by 3 washes in
1× PBS. Antigen retrieval was performed using a micro-
wave defixation method. Slides were microwaved at a
slow boil for 10 minutes in citrate buffer (0.01 M sodium
citrate pH 6.5) then incubated at rest for twenty minutes,
then washed in 3 changes of 1× PBS and blocked using 2%
normal calf serum in PBS for 20 minutes at room temper-
ature (RT).
Sections were labeled with antibodies to SDF-1 (Santa
Cruz cat # sc-6193, goat, recognizes both SDF-1α & β
splice variants). SDF-1 signal was detected by utilizing
either a biotin/avidin (Vector Elite ABC kit) or peroxidase
anti-peroxidase (PAP; Sternberger) amplification system
and visualized with Cy3 conjugated antibody (Jackson
ImmunoResearch Laboratories). In some instances dual
labeling for SDF-1 and a second antigen was utilized to
identify the phenotype of SDF-1 expressing cells. For co-
labeling SDF-1 and the astrocyte marker glial fibrillary
acidic protein (GFAP) a rabbit anti-GFAP antibody
(DAKO cat# Z0334) was used, for oligodendricytes anti-
CNPase (Sigma cat# C5922, mouse) and the biotinylated
lectin Ricinus Communis Agglutinin I (RCA 1, Vector cat# B-
1085, detects unblocked N-Acetyl galactosamine and gal-
atose) for the visualization of endothelial cells and micro-
glial cells [13,36]. All antibodies (and RCA-1) were
allowed to incubate at room temperature for one hour
and washed four times (1× PBS 5 minutes each). All pri-
mary antibodies were detected using indirect staining
with a secondary, fluorescent antibody. Cy3 anti-Goat
(Jackson # 705-165-147), diluted 1:400, was used to visu-
alize SDF-1 in all cases. FITC anti-rabbit (Jackson # 711-
095-152), diluted 1:100, was used to visualize GFAP.
Strepavidin FITC (Jackson #016-010-084), diluted 1:100,
was used to visualize biotinylated RCA. FITC anti-mouse
(Jackson #715-095-151), diluted 1:100, was used to visu-
alize CNPase. Slides were rinsed in 4 changes of PBS for 5
minutes each. Negative controls consisted of preabsorb-
ing 660 ng/ml, (4.3 pM/ml) the SDF-1 antibody (Santa
Cruz cat # sc-6193, goat) with 1.5 ng/ml (43 pM/ml) of
recombinant murine SDF-1α (Peprotech # 250-20A) at
37°C for 1 hour prior to use or leaving off the primary
antibody. Cell nuclei were counterstained with bis-benz-
imide (Sigma, 10 mg/ml stock diluted 1:12,000 in phos-
phate buffered saline) for 8 minutes then given a final
wash prior to coverslipping with Vectashield mounting
media (Vector Labs #H-1000).
Western blotting
Recombinant murine SDF-1α (25 & 100 ng) was run on a
Novex NuPage 10% Bis-Tris Gel (Invitrogen
NP0302BOX) with MES buffer at 75 volts then transferred
to a 0.2 um PVDF membrane (Millipore Immobilon PSQ
#ISEQ00010). The blot was blocked with 4% cold water
fish gelatin (Sigma #G-7765) in PBS at room temperature
for 1 hour. The SDF-1 antibody (Santa Cruz cat # sc-6193,
goat) was incubated shaking (1:100, 10 ug/ml) overnight
at 4°C. The blot was rinsed, then washed 2 times for 10
minutes each in PBS with 0.5% Tween-20 (Fisher #BP337-
500). The anti-SDF-1 antibody was detected with an anti-
goat secondary antibody conjugated with HRP (Jackson
ImmunoResearch #705-035-003, 1:50,000) for 1 hour at
room temperature. The blot was washed again (3 times for
10 minutes each in PBS with 0.5% Tween-20 and 1 time
with PBS only), developed with ECL detection reagent
(Amersham # RPN2109D1) and exposed to X-Ray film
(Fujifilm Super RX #100NIF).
Confocal imaging
Confocal imaging was used to confirm dual labeling with
a Zeiss 510 laser scanning confocal microscope (Zeiss
LTM software) as previously described [13,36]. The objec-
tive used was Zeiss 63× C-Apochromat 1.2NA. To excite
the FITC fluorochrome (green), a 488-nm laser line gener-
ated by an argon laser was used, and for the Cy3 fluoro-
chrome (red), a 543-nm laser from a HeNe laser was used.
Filter sets used were a bandpass 500- to 600-filter ("green"
channel) and a long-pass 585- to 650-nm filter ("red"
channel). We identified cells that were labeled for SDF-1
and either GFAP or RCA with 1-µm step Z series.
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